Anzeige
Mehr »
Dienstag, 10.03.2026 - Börsentäglich über 12.000 News
Das Triple-Discovery-Setup, das der Markt noch nicht begriffen hat!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
290 Leser
Artikel bewerten:
(1)

Datatrak International: DATATRAK ePRO/eCOA Solution Expands Decentralized Trial Platform

Device-agnostic ePRO that is BYOD (bring your own device) with email/SMS reminders, patient portals, and unified reporting across EDC and eDiaries

AUSTIN, TX / ACCESS Newswire / March 10, 2026 / DATATRAK Powered by Fountayn, a unified eClinical and decentralized clinical trial (DCT) platform, today announced the availability of its enhanced electronic patient-reported outcomes (ePRO) and eCOA solution, designed to help sponsors, CROs, and sites collect high-quality patient data for hybrid and decentralized clinical trials. Built on DATATRAK's core eClinical platform, the ePRO module can be deployed as a standalone solution or tightly integrated with the DATATRAK EDC to support end-to-end digital trials.??

DATATRAK ePRO is a device-agnostic, true BYOD solution that allows patients to use their own smartphones, tablets, or computers, reducing study costs and barriers to participation. Study teams can configure eDiaries and electronic clinical outcome assessments (eCOA) using the same eCRF design toolkit they rely on for EDC casebooks, enabling faster start-up and consistent design across all data capture tools.?

"Our customers want ePRO that is flexible, affordable, and fully connected to their EDC - not another silo," said Alex Tabatabai, CEO, DATATRAK Powered by Fountayn. "With DATATRAK ePRO, sponsors and CROs can design and launch eDiaries and eCOA quickly, send automated email and SMS reminders, and analyze compliance alongside EDC casebook data, all within a single, unified platform."?

Standalone ePRO or Fully Integrated with EDC

DATATRAK's ePRO solution is built on the same core platform as its EDC, RTSM, CTMS, eTMF, and eConsent tools. Customers can:?

  1. Use ePRO as a standalone product and integrate with third-party EDC or clinical trial systems, or

  2. Add ePRO as a native extension of the DATATRAK EDC to create a unified environment for data capture, randomization, and trial operations.??

Sites can invite and enroll ePRO participants directly from the EDC, link patient-reported outcome data to subject records, and trigger one-time notifications from within the EDC workflow. This tight integration helps reduce manual reconciliation and improves data quality across the study lifecycle.?

Patient Engagement Through Email/SMS and Secure Portal

To support patient engagement and compliance, DATATRAK ePRO includes:?

  1. Email and SMS notifications to remind participants when eDiary or eCOA entries are due

  2. A patient portal with secure PIN sign-in so participants can easily access their tasks and forms

  3. Configurable one-time notifications sent from the EDC to specific participants or cohorts

These communication tools help improve completion rates and provide sites with better visibility into participant status in real time.??

Unified Reporting Across eDiaries and EDC

Flexible reporting tools span both EDC casebooks and eDiaries, enabling study teams to build compliance and performance reports that incorporate patient-reported outcomes alongside other clinical data. This unified view supports better decision-making, early signal detection, and streamlined preparation for data reviews and regulatory inspections.?

With databases hosted in key regions including the United States, Japan, and Europe -and options for additional local data hosting-DATATRAK Powered by Fountayn supports global studies while aligning with regional data privacy and security requirements.??

About DATATRAK

Datatrak is transforming healthcare and life sciences through technological innovations from providing the first EDC technology to offering the first true eSource solution that seamlessly integrates all aspects of clinical trial data management including EDC, RTSM, RBM, eTMF, CTMS, ePRO, eConsent, Endpoint Adjudication, Imaging Data, Safety, Inventory Management, and Enterprise Management of Automated Alerts, Workflows, Documents, Timelines, and Global Oversight. No other company has been innovating in healthcare and life sciences as long as Datatrak. For over thirty years clinical trial professionals have trusted Datatrak for reliable and secure technology solutions. Datatrak complies with the highest Quality Assurance standards that are 21 CFR Part 11, GDPR, GCP, HIPAA, and CDISC compliant that are fully validated by our experienced team of software quality engineers. Datatrak's cloud-based platform is trusted in 83 countries, 6 continents, for over 10,000 clinical trials. Datatrak is based in Austin, Texas and has team members and data hosting infrastructure in its key service regions of the United States, Europe, and Japan. For more information, visit www.datatrak.com or www.fountayn.com.

Contact:

Sales Department
sales@fountayn.com

SOURCE: Datatrak International



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/computers-technology-and-internet/datatrak-epro%2fecoa-solution-expands-decentralized-trial-platform-1145955

© 2026 ACCESS Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.